Mazen, an animal health company developing oral vaccines administered through animal feed, announced the closing of its Series A funding round, in which it raised $11.2 million. According to a release, Mazen’s technology eliminates issues associated with injectable vaccines like higher costs and the need for labor.

“Our investors are seeing the tremendous potential of the technology platform to deliver better vaccines more efficiently,” CEO Jenny Filbey said. “In fact, the technology can help achieve better animal health through disease prevention – rather than treatment – and improve economics, stewardship and sustainability.”

The funding round was led by Fall Line Capital and included all seed investors, including Next Level Ventures, Kent Corporation, Ag Startup Engine, Ag Ventures Alliance, ISA Ventures and Summit Ag.